I-Mab Securities Lawsuit Investigation

Shamis & Gentile P.A., a law firm that advocates for investors who are victims of securities fraud, is investigating potential claims against I-Mab (IMAB)

If you purchased or acquired I-Mab securities between it's January 2020 IPO and October 16, 2025, and suffered losses, you may be eligible to join this securities investigation and seek compensation.

About I-Mab

I-Mab, headquartered in Rockville, Maryland, is a global biopharmaceutical company focused on developing and commercializing innovative therapies for cancer and autoimmune diseases.

Potential Concerns Under Investigation

Lawyers are investigating whether I-Mab may have made misleading statements or omitted material facts during the period from January 2020 to October 16, 2025. The investigation may include the company’s public statements about its business model, financial condition, and clinical progress, and the impact of strategic changes announced in October 2025.

Beginning in January 2020, I-Mab priced its U.S. initial public offering at $14 per ADS and began trading on Nasdaq as IMAB.

On September 4, 2020, the company and AbbVie announced a global collaboration for lemzoparlimab that included $200 million in upfront and near-term milestone payments and up to $1.74 billion in potential milestones.

On May 26, 2022, I-Mab reported Phase 2 data for uliledlimab (CD73) showing safety and encouraging signals in non small cell lung cancer. On March 31, 2023, the company provided business and corporate updates that included enrollment progress in the uliledlimab program. On September 25, 2023, AbbVie terminated the 2020 CD47 collaboration.

In April 2024, the company announced the divestiture of its China operations. In 2024 updates, including third quarter 2024 results, I-Mab described cash resources and progress across its pipeline. In January 2025 the company identified givastomig as its lead clinical program, followed by a first quarter 2025 update highlighting continued progress.

On October16, 2025, I-Mab announced a plan to transform into a “hub and spoke” global biotech platform, pursue a Hong Kong IPO, and rebrand as NovaBridge Biosciences in a strategic transformation announcement. On this news, the stock declined from a $6.56 close on October 16, 2025 to a $5.77 October 17, 2025, causing significant investor losses.

Your Rights and Next Steps

Investors who purchased I-Mab securities between January 2020, and October 2025, and suffered financial losses may have important legal rights. This is currently an investigation, not a filed lawsuit. The investigation may lead to a class action lawsuit if sufficient evidence of potential securities violations is found.

Lawyers are ready to help investors understand their rights and evaluate whether they may be eligible to participate in any future class action.

Investors are encouraged to gather documentation of their purchases, sales, and losses in I-Mab securities during the class period. By participating in the investigation, investors can help ensure that their interests are represented and may contribute to potential recovery efforts.

You May Be Entitled to Compensation

Securities investigations are time-sensitive. If you purchased or acquired I-Mab securities and experienced losses during the relevant period, you may be eligible to join any potential class action and seek compensation for your damages.

To protect your rights and participate in the investigation, complete the form below.